Several studies have suggested the potential impact of proteases in AML patients, and it is known that cathepsin B and cathepsin L are able to convert pro-urokinase plasminogen activators to their active forms, which are also highly expressed in AML and are associated with a poor prognosis [55]. This evidence concerns the gene CTSB and acute myeloid leukemia.